- New developments
- Toxicities of therapy
- Living well—preservation of performance status
- Developing the research in supportive care
- Psychology/QOL/palliative care
The course is aimed at clinical nurse specialists, GPs, oncologists, general physicians, emergency physicians, palliative care physicians, medical trainees, research nurses, acute oncology nurses and all allied health professionals involved in cancer treatment options.
PAXMAN Scalp Cooling
The PAXMAN Scalp Cooling System, developed by the Paxman family reduces chemotherapy-induced alopecia (CIA) in cancer patients. The concept behind the system came when the mother of 4, Sue Paxman, experienced first-hand the trauma of CIA. Now, the world’s leading manufacturer and supplier of scalp cooling equipment, PAXMAN have close to 4,000 Scalp Cooling Systems installed worldwide. PAXMAN scalp cooling is available in over 350 treatment centers throughout the USA, including all the 5 highest-ranked cancer centers in the USA.
As healthcare professionals, you understand the extent to which CIA can compromise a patient’s quality of life, negatively impacting on body image, self-esteem and depriving patients of their privacy. The prospect of CIA sometimes causes patients to refuse treatment.
A proven way of combatting CIA, scalp cooling can result in a high level of retention or completely preserve the hair. For patients, this means the opportunity to regain some control, maintain privacy and encourage a positive attitude towards treatment.
The NCCN® Clinical Practice Guidelines in oncology (Version 1.2019) recommend scalp cooling as a category 2A treatment option for patients with invasive breast cancer and ovarian cancer, fallopian tube cancer and primary peritoneal cancer who are receiving chemotherapy to reduce the incidence of CIA.
The leading professional organisation for medical oncology, European Society for Medical Oncology (ESMO), has updated Clinical Practice Guidelines for Dermatological Toxicities Related to Anticancer Agents to include the recommendation of scalp cooling for the prevention of CIA as a Category IIB recommendation, as does the ‘Guidance for the management of early breast cancer’ by Cancer Australia.
Investing in scientific development has allowed PAXMAN to attain highest levels of technical precision and efficacy. Clinical trials, research and health service dialogue over the past several decades have been extensive – this remains ongoing. PAXMAN want to work to provide patients with a sense of normalcy during one of the most difficult times of their lives.
With a portfolio spanning from prescription drugs and consumer healthcare products to dermo-cosmetics, Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. Its portfolio includes several global brands and franchises, such as Pierre Fabre Dermatologie and Pierre Fabre Oncologie.
Pierre Fabre is committed to delivering treatment options to patients with cancer and has been working with oncologists for 29 years to make a difference in their clinical practice.
Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognised public-interest foundation, and secondarily by its own employees.
Sign up to our education events mailing list to be kept up to date with this and future events